239 related articles for article (PubMed ID: 27085175)
1. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
2. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
3. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.
Patton K; Aslam S; Shambaugh C; Lin R; Heeke D; Frantz C; Zuo F; Esser MT; Paliard X; Lambert SL
Vaccine; 2015 Aug; 33(36):4472-8. PubMed ID: 26206269
[TBL] [Abstract][Full Text] [Related]
5. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
6. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
8. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
9. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
10. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
11. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
Front Immunol; 2018; 9():295. PubMed ID: 29515589
[TBL] [Abstract][Full Text] [Related]
12. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
13. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM
Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309
[TBL] [Abstract][Full Text] [Related]
14. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
15. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
Falloon J; Talbot HK; Curtis C; Ervin J; Krieger D; Dubovsky F; Takas T; Yu J; Yu L; Lambert SL; Villafana T; Esser MT
Clin Vaccine Immunol; 2017 Sep; 24(9):. PubMed ID: 28679495
[TBL] [Abstract][Full Text] [Related]
16. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
17. Optimization of a methamphetamine conjugate vaccine for antibody production in mice.
Stevens MW; Gunnell MG; Tawney R; Owens SM
Int Immunopharmacol; 2016 Jun; 35():137-141. PubMed ID: 27039212
[TBL] [Abstract][Full Text] [Related]
18. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
[TBL] [Abstract][Full Text] [Related]
19. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.
Ogembo JG; Muraswki MR; McGinnes LW; Parcharidou A; Sutiwisesak R; Tison T; Avendano J; Agnani D; Finberg RW; Morrison TG; Fingeroth JD
J Transl Med; 2015 Feb; 13():50. PubMed ID: 25885535
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]